Clinical Trial

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To assess the efficacy and safety of ASK120067 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor Gefitinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-10-28; most recent amendment 2024-06-12.
Status change: Recruiting → Active, Not Recruiting 2024-06-12
Trial Details
NCT Number NCT04143607
Lead Sponsor Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Conditions Locally Advanced or Metastatic NSCLC
Enrollment 337 participants
Start Date 2019-07-23
Primary Completion 2024-03-31 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-06-14